On April 13, 2009, Pharmacyclics, Inc. a Delaware corporation (the "Registrant"), announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). This is the first Btk selective inhibitor to be tested in humans, and is Pharmacyclics' fourth product in clinical development.

The foregoing description is qualified in its entirety by reference to the Registrant's Press Release dated April 13, 2009, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

(d) Exhibits.

                    Exhibit No.    Description
                       99.1        Press Release of Pharmacyclics, Inc. dated April 13, 2009.


--------------------------------------------------------------------------------
--------------------------------------------------------------------------------